CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 25 enrolled
Drug / intervention
Prednisonedrug
Likely dose
Prednisone 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03023891
NCT03023891Phase 1Completed
CompareCT.gov

Pharmacogenomics of the Variability in the In Vivo Response to Glucocorticoids

Vanderbilt University Medical Center·interventional·Posted Jan 18, 2017·Updated Jun 4, 2020

In Brief

A Phase 1 clinical trial evaluating Prednisone for Glucocorticoids Toxicity and Glucose Intolerance. Completed, enrolled 25 participants across 1 site.

Detailed Summary

This study evaluates the effect of acute administration of oral prednisone in white blood cells counts and glucose tolerance and the relationship of these measures with changes in gene expression in healthy volunteers. White blood cells counts, glucose tolerance and gene expression will be study before and after prednisone administration.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlucocorticoids Toxicity, Glucose Intolerance
CountriesUnited States
CollaboratorsNational Institute of General Medical Sciences (NIGMS)

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 18, 2017
Enrollment StartFeb 15, 2017
Primary CompletionJan 10, 2019
Study CompletionDec 31, 2019
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 9.5 years ago

Interventions

Prednisonedrug

Prednisone 60 mg tablet once